(−)-Epigallocatechin Gallate Targets Notch to Attenuate the Inflammatory Response in the Immediate Early Stage in Human Macrophages by Tengfei Wang et al.
April 2017 | Volume 8 | Article 4331
Original research
published: 10 April 2017
doi: 10.3389/fimmu.2017.00433
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Jixin Zhong, 
Case Western Reserve University, 
USA
Reviewed by: 
Yanlin He, 
Baylor College of Medicine, USA  
Xuhui Feng, 
Indiana University, USA  
Yonglin Chen, 
Yale University, USA  
Penghua Yang, 
University of Maryland School of 
Medicine, USA
*Correspondence:
Shumei Hao  
haosm@sina.com; 
Xuanjun Wang  
wangxuanjun@gmail.com; 
Jun Sheng  
shengj@ynau.edu.cn
Specialty section: 
This article was submitted 
to Inflammation, 
a section of the journal 
Frontiers in Immunology
Received: 26 January 2017
Accepted: 28 March 2017
Published: 10 April 2017
Citation: 
Wang T, Xiang Z, Wang Y, Li X, 
Fang C, Song S, Li C, Yu H, Wang H, 
Yan L, Hao S, Wang X and Sheng J 
(2017) (−)-Epigallocatechin Gallate 
Targets Notch to Attenuate the 
Inflammatory Response in the 
Immediate Early Stage in Human 
Macrophages. 
Front. Immunol. 8:433. 
doi: 10.3389/fimmu.2017.00433
(−)-epigallocatechin gallate Targets 
notch to attenuate the inflammatory 
response in the immediate early 
stage in human Macrophages
Tengfei Wang1,2, Zemin Xiang2,3, Ya Wang2, Xi Li2, Chongye Fang2, Shuang Song2,  
Chunlei Li2, Haishuang Yu2, Han Wang2, Liang Yan4, Shumei Hao3*, Xuanjun Wang2,3* and 
Jun Sheng2,3*
1 College of Life Science, Jilin University, Changchun, China, 2 Key Laboratory of Pu-er Tea Science, Ministry of Education, 
Yunnan Agricultural University, Kunming, China, 3 State Key Laboratory for Conservation and Utilization of Bio-Resources in 
Yunnan, Kunming, China, 4 Pu’er Institute of Pu-erh Tea, Pu’er, Yunnan, China
Inflammation plays important roles at different stages of diabetes mellitus, tumorigenesis, 
and cardiovascular diseases. (−)-Epigallocatechin gallate (EGCG) can attenuate inflam-
matory responses effectively. However, the immediate early mechanism of EGCG in 
inflammation remains unclear. Here, we showed that EGCG attenuated the inflammatory 
response in the immediate early stage of EGCG treatment by shutting off Notch signaling 
and that the effect did not involve the 67-kDa laminin receptor, the common receptor 
for EGCG. EGCG eliminated mature Notch from the cell membrane and the nuclear 
Notch intercellular domain, the active form of Notch, within 2 min by rapid degradation 
via the proteasome pathway. Transcription of the Notch target gene was downregulated 
simultaneously. Knockdown of Notch 1/2 expression by RNA interference impaired the 
downregulation of the inflammatory response elicited by EGCG. Further study showed 
that EGCG inhibited lipopolysaccharide-induced inflammation and turned off Notch 
signaling in human primary macrophages. Taken together, our results show that EGCG 
targets Notch to regulate the inflammatory response in the immediate early stage.
Keywords: (−)-epigallocatechin gallate, notch, macrophages, laminin receptor, inflammation
inTrODUcTiOn
The inflammatory response has an important role at different stages of diabetes mellitus (DM), tumo-
rigenesis, and cardiovascular diseases (1, 2). The inflammatory response is common in the intestine 
and gut due to microbe invasion and damage to cells in epithelial barriers (3). Attenuation of the 
inflammatory response has been considered an important side effect in the therapy and prevention 
of cancer, DM, cardiovascular diseases, and Alzheimer’s disease (4, 5). Compounds in food and 
drinks that can help to attenuate inflammation have been studied for their effects and mechanisms 
of action (6, 7).
(−)-Epigallocatechin gallate (EGCG) is found in Chinese green tea and Pu’er tea. It has been pro-
posed to have strong anti-inflammatory effects (8, 9). The mechanisms of EGCG in the attenuation 
of inflammation have been explored. EGCG downregulates the phosphorylation of nuclear factor-
kappa B (NF-κB), a key regulator of the classical pathway of the inflammation response induced by 
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lipopolysaccharide (LPS) (10). In addition, the 67-kDa laminin 
receptor (67LR), which has been proposed to be a receptor for 
EGCG on cell membranes, has been shown to downregulate the 
anti-inflammatory effects of EGCG (11). However, those stud-
ies have focused on the physiologic response of cells ≥6 h after 
EGCG treatment. Thus, those results may indicate that EGCG 
treatment interferes with mediator proteins in the signal trans-
duction pathway, although the original mechanism of EGCG 
treatment is not clear. Such cells have undergone several rounds 
of signaling processes in ≥6 h, and cytokine release and feedback 
may have already occurred in those cells. To understand the 
detailed mechanisms of EGCG in inflammation, we examined 
the immediate early response of macrophages after EGCG addi-
tion and the underlying mechanisms.
The mechanisms of the inflammatory response have been 
studied extensively. The NF-κB molecule has been considered 
to be a key regulator/mediator of LPS-induced inflammation 
(12). The well-known mitogen-activated protein kinase (MAPK) 
pathway, which plays a key part in many other biologic processes, 
has also been confirmed to participate in the inflammatory 
response (13).
Notch signaling has a role in the development of multicel-
lular organisms (14). Notch has been shown to function during 
development of the immune system, including the maturation 
of T  cells (15). In recent years, the Notch signaling pathway 
has been found to have an essential role in regulation of the 
inflammatory response (16). Notch and toll-like receptor (TLR) 
pathways cooperate to activate canonical Notch target genes, 
including the transcriptional repressors hairy and enhancer of 
split-1 (Hes1) and hairy/enhancer of split related with YRPW 
motif protein 1 (Hey1), and to increase the production of the 
canonical TLR-induced cytokines, tumor necrosis factor (TNF), 
interleukin (IL)-6, and IL-12 (17–19). Cooperation of these 
pathways to increase expression of target genes is mediated by 
the Notch pathway component and transcription factor recom-
bination signal-binding protein for immunoglobulin (Ig) kappa 
J region (17). Basal activation of the Notch signal is required 
to amplify the signal transduction from TLRs. The Jagged-1/
Notch signaling pathway is considered a potential molecular 
mechanism underlying the EGCG attenuation of oxidized 
low-density lipoprotein–induced dysfunction of the vascular 
endothelium (20). Studies have shown that EGCG may prevent 
the uric acid-induced inflammatory effect in human umbilical 
vein endothelial cells in relation to Notch1 (21). The Notch 
pathway has also been proposed to be related to the effects of 
EGCG in the protection of cochlear hair cells from ototoxicity 
and inhibition of the proliferation of colorectal cancer cells (22, 
23). These observations suggest a potential relationship between 
EGCG and the Notch pathway.
Here, we studied the immediate early mechanism of EGCG 
on the inflammatory response induced by LPS in human mac-
rophages derived from THP-1 cells. We found that EGCG did not 
alter the phosphorylation levels of NF-κB or the phosphorylation 
state of the key MAPK molecules p38, extracellular signal–
regulated kinase (ERK), and c-Jun-N-terminal kinase (JNK) 
during the first hour after EGCG treatment. However, EGCG 
suppressed Notch signaling, which is necessary for an increased 
inflammatory response. Knockdown of Notch1/2 expression 
impaired the effects of EGCG upon inflammation.
MaTerials anD MeThODs
cell culture and Transfection
The human monocyte cell line (THP-1) was purchased from the 
Cell Bank in the Chinese Academy of Sciences (Kunming). Cell 
lines were cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% (v/v) fetal bovine serum 
(Biological Industries, USA) and 50  µM β-mercaptoethanol. 
Infection was carried out using Notch 1 or Notch 2 short hairpin 
RNA (shRNA) Lentiviral Particles (Santa Cruz Biotechnologies, 
USA) according to manufacturer instructions.
Macrophage Differentiation
THP-1-derived macrophages were differentiated from THP-1 
by propidium monoazide (PMA) treatment (24). THP-1 cells 
were counted to a density of 5 × 105 cell/mL, and viability was 
>95% as determined by exclusion of Trypan blue dye. Then cells 
were seeded on 60-mm culture dishes (5 × 106 per dish) in RPMI 
1640 supplemented with 10% fetal bovine serum (Biological 
Industries) and treated with PMA (10 ng/mL) for 48 h. This was 
followed by incubation with serum-free buffer for a further 24 h 
at 37°C in a humidified incubator in an atmosphere of 5% CO2. 
THP-1-derived macrophages were washed twice with warm 
RPMI 1640 to remove non-adherent cells.
isolation of Peripheral Blood Mononuclear 
cells (PBMcs) and Macrophage 
Differentiation
Peripheral blood mononuclear cell-derived macrophages were 
obtained from anticoagulated, pathogen-free human periph-
eral blood using Medium for Human Lymphocyte Separation 
(Solarbio, China) in accordance with the manufacturer instruc-
tions. The upper layer was retained as autologous serum, which 
was used to culture PBMC-derived macrophages. The mono-
nuclear cells from PBMCs were washed twice with serum-free 
RPMI 1640 and resuspended in RBPI 1640 with 5% autologous 
serum. Then cells were cultured for 7 days with 50 ng/mL mac-
rophage colony-stimulating factor-1 in a humidified incubator 
(37°C, 5% CO2).
67lr Blockade
THP-1-derived macrophages were incubated with RPMI 1640 
containing 5  µg/mL anti-67LR MLuC5 antibody (Santa Cruz 
Biotechnology) or isotype-matched control mouse IgM (Santa 
Cruz Biotechnology) at 37°C in a humidified incubator contain-
ing 5% CO2 for 1 h before the addition of EGCG or LPS.
assay for inflammatory cytokines
The concentrations of TNF-α and IL 1-β were determined using 
enzyme-linked immunosorbent assay (ELISA) kits (Dakewe, 
China) according to manufacturer instructions. Inflammatory 
cytokines released in the medium were monitored by 
Inflammation Antibody Array 3 (Norcross, USA) according to 
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manufacturer instructions. THP-1-derived macrophages were 
pretreated with EGCG (50  µg/mL) for 30  min and stimulated 
with LPS (200 EU/mL) for a further 3 h. PBMC-derived mac-
rophages were pretreated with EGCG (50 µg/mL) for 30 min and 
stimulated with LPS (200 EU/mL) for a further 3 or 6 h. Data 
were collected using a chemiluminescence imaging system (Fluor 
Chem E; ProteinSimple, USA) and analyzed using the RayBio® 
Human Inflammation Antibody Array 3 Analysis Tool.
reverse Transcription Polymerase chain 
reaction (rT-Pcr) and Quantitative rT-
Pcr
THP-1-derived macrophages were pretreated with EGCG (50 µg/
mL) for 30 min and stimulated with LPS (200 EU/mL) for a fur-
ther 1 h. RNA was isolated using TransZol® (Transgen, China). 
Reverse transcription of RNA was done using a PrimeScript™ 
RT Reagent kit with gDNA Eraser (TaKaRa Bio, Japan). 
Quantitative PCR was carried out on a 7900HT Real-Time PCR 
system (Applied Biosystems, USA) using primers (Table S1 in 
Supplementary Material) for human actin, il1 beta, il6, il8, il10, 
mcp1, ccl3, ccl4, ccl5, tnf alpha, timp2, bhle40, ddit4, hk2, p4ha1, 
pfkfb3, rhou, elmo1, hes1, and hey1 using SYBR Green PCR Master 
Mix (TaKaRa Bio). All reactions were performed in triplicate and 
normalized to actin expression.
immunoprecipitation and Posttranslation 
Modification assay
For immunoprecipitation, cells were treated with indicated 
reagents before lysis in lysis buffer (50  mM Tris-HCl, pH 8.0; 
120 mM NaCl; 0.5% NP-40) supplemented with a protease inhibi-
tor cocktail (Sigma–Aldrich, USA) and phosphatase inhibitor 
cocktail (Sigma–Aldrich). After preclearing with protein A/G 
resin, lysates were incubated with Notch2 antibody for 24 h at 
4°C with gentle rotation. Protein A/G resin was added to lysates 
and incubated for a further 6 h. Then protein A/G resin was spun 
down and washed five times with lysis buffer, and Notch2 was 
eluted with sodium citrate (pH 2.5). Notch2 eluates were neutral-
ized with 1.5  M Tris–Cl (pH 8.8) and incubated at 37°C with 
ataxin-3 and peptide-N-glycosidase F (PNGase F) separately. The 
digested Notch2 was analyzed with a western blotting probe with 
the indicated antibodies.
Western Blotting
Cells were lysed in 150  µL lysis solution (Beyotime, China) 
containing phenylmethylsulfonyl fluoride (1  mM). Whole-
cell lysate samples were separated by 8% sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis and transferred to 
polyvinylidene difluoride membranes (Millipore, USA). The 
latter were blocked in 5% bovine serum albumin and incubated 
with primary antibody overnight at 4°C and incubated with 
horseradish peroxidase-conjugated secondary antibody for 
1  h at room temperature. Antibodies against phospho-NF-κB, 
phospho-Erk1/2, phospho-p38 MAPK, Hes1, Actin, Notch1, and 
Notch2 were purchased from Cell Signaling Technology (USA). 
Anti-rabbit IgG and anti-rabbit IgG were purchased from R&D 
Systems (USA).
notch reporter assays
A total of 293 cells were cotransfected transiently with 16 Notch-
responsive element CSL (CBF1, Suppressor of Hairless, Lag-1, 
CSL)/mini-promoter firefly luciferase reporter (constructed by 
our research team) and constitutively expressed Renilla luciferase 
reporter (pRL-CMV; Promega, USA). EGCG was added alone or 
together with ligand-expressing cells (HepG2 cells) 18  h after 
transfection. Luciferase activities were measured 12–24  h after 
EGCG addition (Dual Glo Luciferase; Promega). Typically, three 
replicates were analyzed for each condition, and values were 
expressed as relative luciferase units (firefly signal divided by the 
Renilla signal).
Molecular interaction assay
To measure a possible direct interaction between Notch and 
EGCG, we prepared the human Notch negative regulation 
region (NRR). The NRR has been considered to have a key role 
in Notch activation. The binding affinity of EGCG and NRR 
was determined using an Octet Red96 system (ForteBio, USA). 
The biotinylated NRR protein was loaded on Super Streptavidin 
biosensors and acted with gradient concentration of EGCG in the 
assay buffer (phosphate-buffered saline, pH 6.5). We measured 
EGCG association and dissociation for 60 s each. Kinetic param-
eters and affinities were calculated from a non-linear global fit 
of the data between EGCG and NRR using Octet Data Analysis 
v7.0 (ForteBio).
statistical analyses
Data are represented as mean ± SD. Data were analyzed using 
Student’s t-test with GraphPad (USA). *p < 0.05, **p < 0.01, and 
***p < 0.001 were considered significant.
resUlTs
egcg attenuated the immediate early 
inflammatory response
To evaluate the direct effects of EGCG on inflammation, human 
macrophages differentiated from THP-1 cells (Figures S1 and 
S2 in Supplementary Material) for 48 h with PMA (10 ng/mL) 
were pretreated with EGCG (50  µg/mL) for 30  min and then 
stimulated with LPS (200 EU/mL) for an additional 6 h. Samples 
of the medium were collected 3  h after LPS stimulation. The 
concentration of major inflammatory cytokines was measured 
using ELISA kits.
Lipopolysaccharide stimulated the release of TNF-α 
(Figure  1A) and IL-1β (Figure  1B) significantly (p <  0.001), 
and EGCG attenuated release of these cytokines (Figures 1A,B) 
in human macrophages. To determine the effects of EGCG 
on inflammation in macrophages, we examined expression 
of inflammatory cytokines in human macrophages in culture 
supernatants collected 3  h post-LPS treatment under identical 
experimental conditions using a human inflammation antibody 
array (RayBio). Expression of all inflammatory cytokines was 
increased significantly (p < 0.05, p < 0.01, or p < 0.001) by LPS 
stimulation, as well as by TNF-α and IL-1β (Figures  1C,D). 
Expression of 24 of 40 inflammatory factors induced by LPS 
FigUre 1 | continued
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was reduced significantly (p < 0.05, p < 0.01, or p < 0.001) by 
EGCG, including IL-1β, IL-6, IL-8, IL-10, monocyte chemo-
tactic protein 1 (MCP-1), macrophage inflammatory protein 
1-alpha (MIP-1α), MIP-1β, IL-12-p70, regulated on activation, 
normal T  cell expressed and secreted, TNF-α, and TIMP-2 
(Figures  1C,D; Table S2 in Supplementary Material). With 
regard to expression of the other 16 cytokines, the EGCG-
treated sample showed downregulation, but this value was not 
significant (0.05 < p < 0.45) compared with that obtained for the 
LPS sample (Figures 1C,D). These results suggested that EGCG 
inhibited the release of inflammatory cytokines in the medium in 
THP-1-derived human macrophages during the immediate early 
stage of inflammation induced by LPS.
(−)-Epigallocatechin gallate had been shown to downregulate 
the mRNA levels of inflammatory cytokines in the intermediate 
or longer period of treatment of cells (>6 h). To ascertain whether 
the mRNA level of inflammatory cytokines could be attenuated in 
the immediate early period of EGCG treatment, the expression of 
major cytokines was detected on chips 1 h after EGCG addition 
using real-time PCR. Results showed that the mRNA levels of all 
FigUre 1 | (−)-epigallocatechin gallate (egcg) attenuated the inflammatory response in the immediate early stage. THP-1-derived macrophages were 
pretreated with EGCG (50 µg/mL) for 30 min before exposure to lipopolysaccharide (LPS) (200 EU/mL) for 3 h. Expression of the inflammatory cytokines in the 
culture medium was measured by enzyme-linked immunosorbent assay (a,B) and a RayBio® C-Series human inflammation antibody array (c), and chips were 
scanned and analyzed (D). mRNA levels 1 h after LPS treatment were measured by real-time polymerase chain reaction (e). Data are represented as mean ± SD 
(n = 3). Differences between the two groups were assessed by two-way ANOVA using GraphPad. Representatives of three independent experiments with similar 
results are shown. Results are represented as mean ± SD (*p < 0.05, **p < 0.01, and ***p < 0.001).
5
Wang et al. EGCG Targets Notch Attenuate Inflammation
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 433
measured inflammatory cytokines were decreased immediately 
after EGCG addition (Figure 1E). Taken together, these results 
suggested that EGCG could suppress the production of inflam-
matory cytokines induced by LPS in THP-1-derived human 
macrophages.
egcg attenuated inflammation not 
involved in the classical immune Pathway
Classical NF-κB and MAPK pathways have been proposed as the 
major mechanisms underlying inflammatory signaling. These 
pathways have also been proposed to mediate the effects of EGCG 
on inflammation in the intermediate (>6  h) or longer stages 
(≥12 h). To ascertain whether EGCG attenuated the immediate 
inflammatory response via the same mechanism, we designed 
and undertook intervention studies using EGCG.
The phosphorylation of NF κB and MAPK (i.e., p42/44, p38, 
and JNK) in THP-1-derived human macrophages was detected by 
western blotting after LPS treatment for 30, 60, and 90 min. EGCG 
was added 30  min before LPS. In contrast to the mechanisms 
described for EGCG upon inflammation, the phosphorylation of 
NF κB (Figure 2A), p42/44, and JNK (Figure 2B) was not inhibited 
by EGCG within the first 60 min, and the phosphorylation of p38 
increased upon EGCG addition (Figure 2B). Sixty minutes after 
EGCG addition, NF κB phosphorylation remained unchanged. 
Moreover, the phosphorylation of ERK (p42/44) (Figure 2B) also 
increased upon EGCG addition. Increased phosphorylation has 
been shown to enhance the inflammatory response, and so the 
FigUre 2 | (−)-epigallocatechin gallate (egcg) attenuated inflammation not involved in the classical immune pathway. THP-1-derived macrophages 
were treated with lipopolysaccharide (LPS) (200 EU/mL) for 30, 60, and 90 min by pretreated EGCG (50 µg/mL, 30 min). The major immunological pathways nuclear 
factor-kappa B (NF-κB) (a) and MAPK [p38, p42/44, and c-Jun-N-terminal kinase (JNK)] (B) were detected. n.s., not significant.
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increased phosphorylation of MAPK induced by EGCG could 
not explain the attenuated inflammatory effects of EGCG and nor 
could NF-κB.
egcg Turns-Off notch signaling
The Notch signaling pathway has a pivotal role in the develop-
ment of multicellular organisms. Notch (specifically Notch1) is 
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crucial for lymphocyte development (25). Emerging evidence 
has shown that the Notch pathway anticipates the immune 
response, including inflammation (26). Basal activation of 
Notch1 has been shown to be necessary for enhancement of 
the inflammatory response (27). To ascertain whether EGCG 
attenuates the inflammatory response via the Notch pathway 
immediately after its addition, we examined the Notch1 and 
Notch2 receptors, which are expressed on the surface of human 
macrophages at multiple time points shortly after EGCG treat-
ment. We found that the number of mature Notch1 and Notch2 
receptors was decreased from the cell surface at all time points 
after EGCG treatment and that this process was not dependent 
on LPS stimulation (Figure  3A). Further studies showed that 
mature Notch removed the effects of EGCG in a concentration-
dependent manner (Figure 3B) and that this decreased response 
was rapid (2 min) (Figure 3C). Simultaneously, EGCG treatment 
accelerated the degradation of the nuclear Notch intercellular 
domain (NICD), the active form of Notch, in 2 min (Figure 3D). 
In accordance with this result, a western blotting probe with a 
specific antibody against the new epitope formed after Notch1 
cleavage showed that degradation of the active form of Notch1 
was promoted by EGCG (Figure  3E). These results suggested 
that the basal signaling of Notch was turned off immediately by 
EGCG treatment. In accordance with these results, expression 
of Hes1 (a typical Notch-regulated gene) was downregulated by 
EGCG (Figure 3A). To confirm this result, expression of Notch 
target genes was evaluated using real-time PCR. We found that 
expression of some typical Notch target genes was downregu-
lated by EGCG (Figure 3F), but not all of them. This finding may 
have been due to the complexity of gene transcription, which can 
be influenced by many factors. To evaluate the effects of EGCG 
treatment on gene expression of Notch alone, a dual luciferase 
reporter assay was employed. This assay involves use of the 
luciferase gene, which is controlled by 16×CSL, which contains 
16 major Notch-regulated elements (CSL) connected in a series. 
Results showed that only treatment with EGCG could decrease 
Notch-related luciferase signaling in 293T cells and HepG2/293T 
cocultures (Figure 3G).
To understand the mechanism of Notch suppression induced 
by EGCG, the proteasome inhibitor MG132 was used to pretreat 
macrophages before EGCG addition. Notch degradation was 
inhibited partially by increasing (10–40  µM) concentrations of 
MG132 (Figure 3H). This result showed that MG132 inhibited 
the Notch degradation induced by EGCG. Western blotting 
demonstrated that pre-Notch1/2 accumulated immediately after 
EGCG treatment and that the molecular weight of pre-Notch1/2 
increased over time (Figures 3B,C). The major change in molecu-
lar weight occurred with posttranslational modification of the 
protein, including glycosylation and polyubiquitination. Thus, the 
immunoprecipitated Notch2 from THP-1-derived macrophages 
was treated separately with PNGase F (which removes N-linked 
polysaccharides from the glycosylated protein) or ataxin-3 (an 
enzyme that removes ubiquitin from the target protein). The 
increased molecular weight of the accumulated precursor of 
Notch2 after EGCG treatment (Figures  3B,C) was decreased 
upon treatment with ataxin-3, but not PNGase F (Figure  3I). 
This result confirmed that pre-Notch was highly ubiquitinated 
(but not glycosylated) in EGCG-treated cells. In accordance with 
the MG132-based inhibition of Notch degradation induced by 
EGCG, the Notch mature/active form was overubiquitinated after 
EGCG treatment as demonstrated by an immunoprecipitation–
western blotting experiment using an antibody against Notch or 
ubiquitin separately (Figure 3J). These results demonstrated that 
EGCG induced switching off of the Notch signal by inducing 
Notch degradation via a proteasome pathway.
notch is a new Target of egcg 
independent of 67lr
67-kDa laminin receptor has been proposed to be a cell surface 
target for EGCG to mediate its biologic activity (11). Scholars 
have reported that EGCG downregulates the inflammatory 
response in mouse macrophages via 67LR (28). However, 
those studies confirmed the effects at long time points (typi-
cally >6 h). To ascertain whether 67LR mediated the effects of 
EGCG on Notch and inflammation in the immediate early stage 
in THP-1-derived human macrophages, cells were pretreated 
for 1 h with the anti-67LR antibody MLuC5 (5 µg/mL), which 
is known to block the interaction between EGCG and 67LR. 
MluC5 blockade did not affect the suppression of Notch by 
EGCG (Figure 4A) or expression of the typical Notch-regulated 
protein Hes1 (Figure  4A). The effects of EGCG on the NF-κB 
(Figure S3A in Supplementary Material) and MAPK (Figure S3B 
in Supplementary Material) pathways were unaltered by MluC5 
blockade 30 min after EGCG addition. To study the inflammatory 
effects of EGCG at the immediate early stage, MLuC5-treated 
macrophages were pretreated for 30 min with EGCG before LPS 
exposure. Production of TNF-α and IL-1β in culture supernatants 
from human macrophages induced by LPS was inhibited mark-
edly by EGCG treatment in anti-67LR antibody-treated cells and 
control cells (Figures 4B,C). To determine the influence of 67LR 
blockade on the inflammation-attenuated effects of EGCG in 
human macrophages, we examined the inflammatory cytokines 
released in culture supernatants 3 h after LPS treatment using a 
human inflammation antibody array (RayBio). Expression of 27 
of 40 inflammatory factors induced by LPS stimulation, as well 
as TNF-α and IL-1β (Figures 4B,C; Table S3 in Supplementary 
Material), was reduced significantly (p  <  0.05, p  <  0.01, or 
p  <  0.001) by EGCG when macrophages were blocked by 
MluC5 (Figures 4D,E). These results were comparable to those 
of the non-blocking experiments (Figures  1C,D; Table S3 in 
Supplementary Material). The expression of major inflammatory 
cytokines downregulated by EGCG, such as TNF-α, IL-1β, IL-6, 
IL-8, IL-10, MCP-1, IL-6sR, CCL5/RANTES, and TIMP-2, was 
not affected by MluC5 pretreatment.
To measure a possible direct interaction between Notch and 
EGCG, we prepared the human NRR1. The NRR1 is located 
outside the cell membrane and has been considered to have a key 
role in Notch1 activation. Binding assays showed that NRR1 had 
a direct interaction with EGCG and that the affinity of EGCG to 
NRR1 was 2.44 × 10–6 (Figure 4F).
Taken together, these results demonstrated that 67LR had no 
influence on the inflammation-attenuated effects of EGCG at the 
immediate early stage. Thus, Notch is a new target of EGCG.
FigUre 3 | continued
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Knockdown of notch 1/2 impaired the 
effects of egcg on inflammation
To investigate whether the effects of EGCG on cellular responses 
to LPS stimulation are dependent on Notch, we undertook 
shRNA knockdown of Notch 1/2 in THP-1 cells. THP-1 cells 
were infected with Notch1/2 shRNA lentiviral particles 
(Santa Cruz Biotechnology) and screened with puromycin 
(5  µg/mL) to silence expression of Notch1 or Notch2. Notch 
FigUre 3 | continued
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FigUre 3 | (−)-epigallocatechin gallate (egcg) shuts off the notch signal. (a) THP-1-derived macrophages were treated with lipopolysaccharide (LPS) 
(200 EU/mL) for 30, 60, and 90 min by pretreated EGCG (50 µg/mL, 30 min). (B) THP-1-derived macrophages were treated with EGCG (50, 25, 12.5, 6.3, 3.1, and 
1.6 µg/mL) for 30 min. (c) THP-1-derived macrophages were treated with EGCG (50 µg/mL) from 2 to 120 min. (D) THP-1-derived macrophages were treated with 
EGCG (50 µg/mL) from 2 to 120 min. Notch intercellular domain (NICD) of Notch1 and Notch2 located in the nucleus was detected, with TATA-binding protein (TBP) 
used as the internal control. (e) THP-1-derived macrophages were treated with EGCG (50 µg/mL) for 30 min, and lysates were analyzed by a western blotting probe 
with an antibody recognizing the epitope specific for active Notch1. (F) THP-1-derived macrophages were pretreated with EGCG (50 µg/mL) for 30 min and 
exposed to LPS (200 EU/mL) for 1 h. mRNA expression was measured by real-time polymerase chain reaction. (g) Notch report assays: 293/16CSL alone (left) and 
293/16CSL with HepG2 coculture (right). (h) THP-1-derived macrophages were treated with EGCG (50 µg/mL) for 30 min with or without MG132 (10, 20, and 
40 µM). (i) Immunoprecipitation was used to pull-down Notch from macrophage cell lysates. The Notch eluate was digested with PNGase F (left) and ATX-3 (right) 
and probed with the appropriate antibody. (J) Immunoprecipitation undertaken with antibody against the C-terminal of Notch1. The western blotting membrane was 
probed with an antibody against Notch1 or ubiquitin separately. Data are represented as mean ± SD (n = 3). Differences between the two groups were assessed by 
two-way ANOVA using GraphPad. Representatives of three independent experiments with similar results are shown. Results are represented as mean ± SD 
(*p < 0.05, **p < 0.01, and ***p < 0.001). n.s., not significant.
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FigUre 4 | continued
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1/2 silencing was confirmed by western blotting (Figure 5A). 
Notch 1/2-silenced THP-1 cells were treated with PMA (10 ng/
mL) for 48 h to obtain macrophages that were similar to wild-
type macrophages. Notch 1/2-silenced macrophages were 
stimulated with LPS (200 EU/mL) and pretreated (or not) for 
30 min with EGCG. Expression of the inflammatory cytokines 
in samples 3 h after LPS addition was measured using a human 
inflammation antibody array (RayBio). Results showed that 
Notch1/2 knockdown impaired the attenuated effects of EGCG 
on release of inflammatory cytokines (Figures 5B–E). Further 
analyses of the inflammation array results revealed that Notch1 
knockdown blocked the attenuated effects of EGCG in 30 
of 40 of the inflammatory cytokines and that knockdown of 
Notch2 blocked the attenuated effects of EGCG in 31 of the 
FigUre 4 | continued
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FigUre 4 | notch is a new target of (−)-epigallocatechin gallate (egcg) independent of the 67-kDa laminin receptor (67lr). THP-1-derived 
macrophages were preincubated with 67LR antibody (5 µg/mL) for 1 h and then treated with EGCG (50 µg/mL) for 30 min. Cell lysates were probed with Notch1/2 
and hairy and enhancer of split-1 (Hes1). (a) THP-1-derived macrophages were pretreated with EGCG (50 µg/mL) for 30 min before exposure to lipopolysaccharide 
(LPS) (200 EU/mL) for 3 h. Cell lysates were probed with Notch1/2 and Hes1 (a). Expression of the inflammatory cytokines in THP-1-derived macrophages in the 
culture medium was measured by enzyme-linked immunosorbent assay (B,c) and RayBio C-Series human inflammation antibody array (D). Chips were scanned 
and analyzed (e). (F) Interaction between EGCG and NRR1 was measured on an Octet Red96 system with association and dissociation for 300 s, respectively. The 
concentration of EGCG used was a double dilution starting from 40 µM. Kinetic parameters and affinities were calculated from a non-linear global fit. Data are 
represented as mean ± SD (n = 3). Differences between the two groups were assessed by two-way ANOVA using GraphPad. Representatives of three independent 
experiments with similar results are shown. Results are represented as mean ± SD (*p < 0.05, **p < 0.01, and ***p < 0.001).
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40 inflammatory cytokines (Figures  5B–E; Tables S3 and S4 
in Supplementary Material). These results demonstrated that 
Notch1/2 knockdown greatly impaired the inflammation-
attenuated effects of EGCG and that Notch1/2 is a major target 
for EGCG for reduction of the inflammatory response in the 
early stage.
We wished to evaluate whether overexpression of the active 
form of Notch could impair the inflammation-attenuated effects 
of EGCG. Hence, NICD-green fluorescent protein, the constitu-
tively active form of Notch1, was overexpressed in THP-1 cells by 
transfection, and the cells were sorted by fluorescence-activated 
cell sorting. However, transfection of the active form of Notch 
did not erase the effects of EGCG (Figure  5F) because EGCG 
treatment led to degradation of the original form and active form 
of Notch (Figure 5G). These data suggested that rapid degrada-
tion of Notch (including the basal active NICD) was induced by 
EGCG treatment. Such treatment also accelerated degradation of 
the active form of Notch (NICD-GFP).
egcg suppressed lPs-induced 
inflammation in human Primary 
Macrophages
We demonstrated that EGCG attenuated the LPS-induced inflam-
mation response via Notch1/2 in THP-1-derived macrophages. 
However, the THP-1 cell is derived from a patient with acute 
monocytic leukemia, and so it may demonstrate different mecha-
nisms with regard to regulation of the inflammatory response. To 
evaluate the effects of EGCG on normal human cells, we exam-
ined the anti-inflammatory effect of EGCG on primary human 
macrophages differentiated from PBMCs collected from healthy 
human donors. Human primary macrophages cultured with 5% 
autologous serum were used in LPS/EGCG experiments. Similar 
to THP-1-derived macrophages, primary human macrophages 
were pretreated for 30 min with EGCG before LPS exposure. In 
accordance with the findings obtained in THP-1 cells, TNF-α 
production in the culture supernatants obtained from primary 
FigUre 5 | continued
15
Wang et al. EGCG Targets Notch Attenuate Inflammation
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 433
human macrophages was increased significantly (p < 0.001) with 
LPS treatment, and LPS-induced production of inflammatory 
cytokines was inhibited significantly (p  <  0.001) in EGCG-
pretreated cells (Figure 6A). EGCG treatment also suppressed the 
expression of Notch1/2 and the typical Notch target protein Hes1 
(Figure 6B). The time course in EGCG-treated human primary 
macrophages showed that EGCG suppressed Notch1/2 at 2 min 
(Figure  6C). Taken together, these results showed that human 
primary macrophages obtained from PBMCs exhibited the same 
effects as THP-1-derived macrophages upon EGCG treatment.
DiscUssiOn
The inflammatory response, specifically that induced by LPS, 
can be elicited in minutes and even seconds (29, 30). The phos-
phorylation and nuclear translocation of the major mediators 
of inflammation, such as NF-κB, can be detected within 1 min 
(31, 32). Upregulated expression of the genes of inflammatory 
cytokines can be observed within several minutes using real-time 
PCR. Moreover, the release of the “first round” of inflammatory 
cytokines, such as TNF-α, can be measured by ELISA 2–3  h 
FigUre 5 | continued
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FigUre 5 | notch1/2 knockdown impaired the effects of (−)-epigallocatechin gallate (egcg) on inflammation. After knockdown of Notch1 or Notch2 
through infection by lentivirus particles, inflammation experiments were done the same way as for wild-type THP-1-derived macrophages. Knockdown of Notch1 or 
Notch2 was confirmed by western blotting (a). Notch1/2 knockdown macrophages were pretreated with EGCG (50 µg/mL) for 30 min before exposure to 
lipopolysaccharide (LPS) (200 EU/mL) for 3 h. Expression of the inflammatory cytokines in the culture medium was measured by a RayBio C-Series human 
inflammation antibody array: Notch1 knockdown (B) and Notch2 knockdown (D). Chips were scanned and analyzed: Notch1 knockdown (c) and Notch2 
knockdown (e). Notch intercellular domain (NICD)-green fluorescent protein (GFP)-overexpressed macrophages were pretreated with EGCG (50 µg/mL) for 30 min 
and exposed to LPS (200 EU/mL) for 3 h. Levels of tumor necrosis factor (TNF)-α and interleukin (IL)-1β in the culture medium were measured by enzyme-linked 
immunosorbent assay (F), and cell lysates were analyzed by western blotting and a probe with antibody against Notch1 or GFP separately (g). Data are represented 
as mean ± SD (n = 3). Differences between the two groups were assessed by two-way ANOVA using GraphPad. Representatives of three independent experiments 
with similar results are shown. Results are represented as mean ± SD (*p < 0.05, **p < 0.01, and ***p < 0.001). n.s., not significant.
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after LPS addition. Three hours later, the released cytokines in 
the medium can engage with receptors on the cell membranes 
of cells to initiate the “second round” of the cellular response, 
including inflammation. Taken together, these events complicate 
examination of the mechanism underlying regulation of the 
inflammatory response and interference by special reagents. 
Thus, it is important to uncover the original mechanism or target 
in the immediate early stage.
(−)-Epigallocatechin gallate is a major bioactive compound 
found in Chinese green tea. It has been shown to attenuate the 
inflammatory response (33). The mechanisms of EGCG upon 
inflammation have been explored in detail. However, those 
FigUre 6 | (−)-epigallocatechin gallate (egcg) suppressed lipopolysaccharide (lPs)-induced inflammation in human primary macrophages. Human 
primary macrophages derived from peripheral blood mononuclear cells (PBMCs) cultured with autologous serum were pretreated with EGCG (50 µg/mL) for 30 min 
and exposed to LPS (200 EU/mL) for 3 h. Expression of inflammatory cytokines was measured by enzyme-linked immunosorbent assay (a). Cell lysates 30 min 
after EGCG treatment were analyzed by western blotting and probed with hairy and enhancer of split-1 (Hes1) antibody (B). Cell lysates from time course 
experiments of EGCG treatment were analyzed by western blotting and probed with a Notch1/2 antibody (c).
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studies focused on the intermediate or longer stages, which is 
typically >6 h or overnight, following EGCG treatment (34, 35). 
EGCG has been shown to downregulate the phosphorylation 
of key regulators of the classical pathway of the inflammatory 
response, such as NF-κB. In addition, 67LR (which has been 
proposed to be the receptor for EGCG identified from mouse cell 
membranes) has been shown to mediate downregulation of the 
anti-inflammation effects of EGCG. However, those studies also 
focused on the physiologic responses of cells ≥6 h after EGCG 
treatment. Those data suggest that EGCG treatment interferes 
with the mediator proteins in the signal transduction pathway, 
but the original mechanism of EGCG treatment is not known.
Here, we studied the immediate early response of mac-
rophages after EGCG addition and revealed the mechanism of 
action of Notch. First, the inflammation-attenuated effects of 
EGCG in the immediate early stage were confirmed by measur-
ing cytokine levels in the culture medium and cytokine mRNA 
levels in macrophages. Induction of inflammatory cytokines 
can be measured only 3  h after LPS addition, so ELISA and 
human inflammation chips were employed. EGCG reduced 
the expression of 24 of 40 inflammatory cytokines, and mRNA 
levels decreased in 9 of 10 genes 1 h after LPS addition. These 
results confirm that EGCG attenuates the LPS-induced inflam-
matory response in the immediate early stage. With regard 
to classical inflammation pathways, NF-κB and MAPK were 
examined to ascertain whether they are the major mediators of 
the EGCG-regulated inflammatory response in the immediate 
early stage. Unexpectedly, the NF-κB and MAPK pathways 
were not involved in reducing the anti-inflammatory effects of 
EGCG. However, increased phosphorylation of p38 and ERK 
was observed after EGCG addition (Figure  2B). This finding 
conflicts with data showing that MAPK is inhibited by EGCG 
(36, 37). The active form of the MAPK pathway is considered to 
increase the inflammatory response, even though it is a weaker 
regulator compared with NF-κB in macrophages. The increased 
activation of MAPK by EGCG in the early stage may be due to an 
unknown mechanism of EGCG. These data suggest the EGCG 
may target two signaling pathways that regulate inflammation at 
the early stage: activation of MAPK and shutting down Notch. 
In accordance with this hypothesis, EGCG treatment increased 
the basal inflammatory response due to MAPK activation when 
Notch1 was knocked down.
Based on the potential relationship between EGCG/Notch 
shown previously and knowledge of the role of Notch in the 
inflammatory process, Notch signaling was examined for mature 
Notch receptors and the active form of Notch, NICD (which is 
located in the nucleus). We found that the Notch receptor on cell 
membranes and the basal signal of NICD in the nucleus were 
erased 2  min after EGCG addition. Further study showed that 
the Notch signal shut-off by EGCG was concentration depend-
ent and was not dependent on LPS treatment. Consistent with 
the suppression of Notch signaling, the mRNA levels of typical 
Notch-regulated genes were downregulated following EGCG 
treatment, including the protein levels of Notch target genes such 
as HES-1. These results demonstrate that basal Notch signaling 
was suppressed by EGCG. To evaluate the Notch-suppressive 
effect of EGCG in live cells, we undertook a Notch reporter assay 
in 293T cells transfected with pCMV/R-Luc and a firefly lucif-
erase Notch reporter plasmid. We constructed them by placing 
the multiple NICD binding sequence (16CSL) upstream of the 
mini-promoter to control expression of the firefly luciferase gene. 
Coculture of 293T cells with HepG2 (used to provide the ligand 
for Notch activation) and 293T  cells alone showed that Notch 
signaling was suppressed upon EGCG treatment. The protea-
some inhibitor MG132 inhibited the Notch degradation induced 
by EGCG. Consistent with this result, the increase in molecular 
weight of pre-Notch2 induced by EGCG was confirmed due to 
multiple ubiquitination. Also, the ubiquitination level of mature/
active Notch was increased by EGCG treatment. These results 
show that EGCG suppresses Notch signaling via a proteasome 
pathway.
We revealed that Notch localized on cell membranes can be a 
target of EGCG to attenuate the immune response in the immedi-
ate early stage. However, another surface protein, 67LR, has been 
shown to mediate the attenuated effect of the immune response by 
EGCG. To determine whether the effects of EGCG on Notch are 
67LR dependent, the 67LR-blocking antibody MluC5 (which has 
been shown to block the 67LR-dependent effects of EGCG) was 
used in EGCG/Notch experiments to block the potential effects of 
EGCG/67LR on Notch. 67LR blockade did not impair the effects 
of EGCG on the immune response and Notch. These results also 
show that the effects of Notch by EGCG are not dependent on 
67LR and that EGCG interacts with the NRR1 located outside the 
cell membrane of mature Notch1 at high affinity. Hence, Notch is 
a new target of EGCG that can modulate the immune response at 
the immediate early stage.
To evaluate the necessity of Notch in the immune response 
induced by EGCG, Notch1/2 was knocked down by infecting 
THP-1 cells with Notch1/2 shRNA lentiviral particles. The EGCG/
Notch experiments done in macrophages derived from Notch1/2 
knockdown THP-1 cells showed that knockdown of Notch1/2 
lowered the strength of the immune response induced by LPS 
and impaired the attenuated effects of EGCG in the immediate 
early stage. The NICD overexpression experiment didn’t show 
new results due to the transfected NICD is promoted to degrada-
tion by the EGCG treatment also. A basal active Notch signal 
is necessary for amplification of the inflammatory response, so 
Notch1/2 knockdown can decrease the severity of inflammation. 
Also, EGCG cannot lower the inflammation further if Notch1/2 
has been knocked down (Figure S4 in Supplementary Material). 
Hence, we can conclude that Notch is the primary target of EGCG 
to downregulate inflammation in wild-type macrophages. Taken 
together, these results are consistent with previous reports on 
the function of Notch in the immune response and provide new 
information. We also carried out the EGCG/Notch experiments 
on primary human macrophages differentiated from PBMCs 
obtained from healthy donors. Those results confirmed the effects 
of EGCG on Notch and the immune response.
Interestingly, we showed that the Notch shut-off by EGCG is 
not dependent on LPS treatment and last from minutes to over 
6–18 h during the EGCG treatment (Figure S5 in Supplementary 
Material). These results suggest that the interaction between 
Notch and EGCG is likely to be a conservative biochemical reac-
tion in other types of cells, not just macrophages. Attenuation 
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of the inflammatory response could be just one of the effects of 
EGCG/Notch in macrophages. There may be diverse effects upon 
different cell types by EGCG due to the multiple functions of the 
Notch receptor (38).
In summary, we examined the immediate early mechanism of 
EGCG on the inflammatory response induced by LPS in human 
macrophages. We found that shutting off of Notch signaling is 
a key event in the inflammation–attenuation effects induced by 
EGCG in the immediate early stage.
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